Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-05
2011-07-05
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S328000, C544S369000, C548S205000
Reexamination Certificate
active
07973045
ABSTRACT:
The invention provides anhydrous forms of dasatinib, methods for their preparation, and pharmaceutical compositions thereof.
REFERENCES:
patent: 4728653 (1988-03-01), Campbell et al.
patent: 5250534 (1993-10-01), Bell et al.
patent: 6333198 (2001-12-01), Edmeades et al.
patent: 6596746 (2003-07-01), Das et al.
patent: 6976694 (2005-12-01), Das et al.
patent: 7091223 (2006-08-01), Das et al.
patent: 7125875 (2006-10-01), Das et al.
patent: 7153856 (2006-12-01), Barrish et al.
patent: 7189854 (2007-03-01), Das et al.
patent: 7408069 (2008-08-01), Schaefer et al.
patent: 7491725 (2009-02-01), Lajeunesse et al.
patent: 2005/0176965 (2005-08-01), Chen et al.
patent: 2005/0215795 (2005-09-01), Chen et al.
patent: 2006/0004067 (2006-01-01), Chen et al.
patent: 2006/0211705 (2006-09-01), Arora et al.
patent: 2007/0037978 (2007-02-01), Schaefer et al.
patent: 2007/0219370 (2007-09-01), Sun et al.
patent: 2009/0149650 (2009-06-01), Chen et al.
patent: 463756 (1992-01-01), None
patent: WO 00/62778 (2000-10-01), None
patent: WO 2004/085388 (2004-10-01), None
patent: WO 2005/076990 (2005-08-01), None
patent: WO 2005/077945 (2005-08-01), None
patent: WO 2007/019210 (2007-02-01), None
patent: WO 2007/035874 (2007-03-01), None
Caira, “Crystalline Polymorphism of Organic Compounds”, Topics in Current Chemistry, Springer, Berlin, DE, Jan. 1, 1998, vol. 198, p. 163-208.
Das et al., “2-aminothiazole as a Novel Kinase Inhibitor Template. Structure-Activity Relationship Studies Toward the Discovery of N-(2-Chloro-6-methylphenyl)-2[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan-Src Kinase Inh”, Journal of Medicinal Chemistry, Nov. 2006, vol. 49, No. 23, p. 6819-6832.
Strobel et al., Chemical Instrumentation: A Systematic Approach, 3rd ed., Wiley & Sons: New York, p. 391-393, 879,894, 922, 924, 925, 953 (1989).
Snyder et al., Introduction to Modern Liquid Chromatography, 2nd ed., John Wiley & Sons, New York, p. 571-572, 549, 552 (1979).
International Search Report and Written Opinion of ISA, dated Oct. 15, 2009, from International Patent Application PCT/IB2008/003862.
Zhao, et al., “A new facile synthesis of 2-aminothiazole-5-carboxylates,” Tetrahedron Letters, 42: 2102-02 (2001).
Aronhime Judith
Faustmann Ji{hacek over (r)}í
Filip{hacek over (c)}ík Ji{hacek over (r)}í
Gabriel Roman
Gavenda Ale{hacek over (s)}
Kenyon & Kenyon LLP
Teva Pharmaceutical Industries Ltd.
Willis Douglas M
Wilson James O.
LandOfFree
Anhydrous form of dasatinib and process for preparation thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anhydrous form of dasatinib and process for preparation thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anhydrous form of dasatinib and process for preparation thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2633693